The IL-1β inhibitor canakinumab in previously treated lower-risk myelodysplastic syndromes: a phase 2 clinical trialJuan José Rodríguez‐Sevilla, Simona Colla, Vera Ademà et al.|Nature Communications|2024Cited by 18
Analysis of distinct <i>SF3B1</i> hotspot mutations in relation to clinical phenotypes and response to therapy in myeloid neoplasiaVera Ademà, Hetty E. Carraway, Yogen Saunthararajah et al.|Leukemia & lymphoma/Leukemia and lymphoma|2020Cited by 7
Distinct Clinical Phenotypes of Patients with Myeloid Neoplasms Carrying SF3B1 Hotspot MutationsJack Khouri, Hetty E. Carraway, Vera Ademà et al.|Blood|2017Cited by 0
CUL1: Novel Therapeutic Target in Myeloid Neoplasms Harboring -7/Del(7q)Vera Ademà, Valeria Visconte, Cassandra M Kerr et al.|Blood|2019Cited by 0
Pharmacologic Normalization of Altered Transcriptome of SF3B1 Mutant Myeloid NeoplasiaValeria Visconte, Jaroslaw P. Maciejewski, Vera Ademà et al.|Blood|2019Cited by 0